Publications by authors named "S Vantyghem"
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
Maxime Jullien Thierry Guillaume Amandine Le Bourgeois Pierre Peterlin Alice Garnier Sophie Vantyghem
Am J Hematol
March 2024
Article Synopsis
- The presence of donor Vγ9Vδ2 T-cells after haploidentical hematopoietic stem cell transplant (h-HSCT) is linked to better disease-free survival, as these cells can target tumor cells without triggering severe side effects.
- A clinical study assessed the safety of generating these T-cells by combining zoledronic acid (ZA) with interleukin-2 (IL-2), showing that the procedure is safe and successfully increases T-cell numbers in patients.
- The study's outcomes suggest potential for further research into using this immunotherapy to reduce relapse rates after h-HSCT, indicating that more extensive trials may come next.
B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Maxime Jullien Amandine Le Bourgeois Marianne Coste-Burel Pierre Peterlin Alice Garnier Sophie Vantyghem
Transplant Cell Ther
May 2022
Little is known about the immune response to SARS-CoV-2 vaccination in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, several studies have reported that adequate protection could be provided to this population. The purpose of this study was to evaluate which factors can predict the efficacy of SARS-CoV-2 vaccination in these specifically immunosuppressed patients.
View Article and Find Full Text PDF